Longeveron touts PhI­Ia Alzheimer's da­ta, but drug's fu­ture re­mains murky

Longeveron re­leased an up­date from a small Phase IIa Alzheimer’s study Thurs­day morn­ing, claim­ing to show a win at the drug’s low dose. But ques­tions …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.